Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Vomiting 5Nausea 5Neoplasms 4Hematologic Neoplasms 4Anorexia 3Multiple Myeloma 2Breast Neoplasms 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Prosthesis Failure 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Gynecologic Cancer 1Cachexia 1Advanced Cancer 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Olanzapine × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

NCT06588413 2024-11-22

FONDO-LOW

Augusta University

Phase 3 Recruiting
172 enrolled
Plasma cell

Multiple Myeloma, Nausea

Data powered by HemOnc (CC BY 4.0) Colophon âš¡